Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Studies of Murine Schistosomiasis Reveal Interleukin–13 Blockade As A Treatment for Established and Progressive Liver Fibrosis

Open access
Chiaramonte, Monica G., Cheever, Allen W., Malley, James D., Donaldson, Debra D., Wynn, Thomas A.·2001·Hepatology

Abstract

In several allergic, autoimmune, and infectious diseases, fibrosis is a major cause of morbidity and mortality. Here, using a model of infection–induced liver fibrosis, we show that interleukin (IL)–13 is required at all stages of Schistosomiasis mansoni infection to induce fibrosis. IL–4 production was preserved in IL–13-deficient mice, yet failed to significantly contribute to the fibrotic response in either acute or chronic infection. Significant fibrosis develops in all infected mice, although the magnitude of the response varies widely in inbred mice. C3H/HeN, BALB/c, and C57BL/6 mice develop high, intermediate, and low levels of fibrosis, respectively. Despite these differences, IL–13 antagonism resulted in a marked amelioration of fibrosis in all strains. The fibrotic mechanism in the high– and low–responder strains was unrelated to their tissue eosinophil or mast cell responses, but did correlate with their patterns of IL–13, IL–10, and interferon gamma (IFN–γ) mRNA expression. Indeed, severe fibrosis correlated with a high IL–13 and low IFN–γ/IL–10 mRNA response. Because fibrotic diseases are typically progressive disorders, an important issue was to determine whether IL–13 inactivation might be used to treat an established and ongoing fibrotic disease. Here, IL–13 antagonism was highly efficacious, even after fibrosis and the Th2 cytokine response were firmly established. These studies demonstrate the central role played by IL–13 in fibrogenesis and suggest that therapeutic approaches aimed at disrupting the IL–13 pathway will be highly effective at preventing fibrotic disease caused by chronic Th2–mediated inflammatory reactions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/jhep.2001.26376

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 174

Metadata

Authors
Chiaramonte, M. G., Cheever, A. W., Malley, J. D., Donaldson, D. D., & Wynn, T. A.
Venue
Hepatology
Published
2001-08
Volume
34
Issue
2
Pages
273-282
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2081802477
Cited by
174
References
3
FWCI
7.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Studies of Murine Schistosomiasis Reveal Interleukin–13 Blockade As A Treatment for Established and Progressive Liver Fibrosis. https://app.cochat.ai/papers/10.1053/jhep.2001.26376
The paper
Chiaramonte, M. G., Cheever, A. W., Malley, J. D., Donaldson, D. D., & Wynn, T. A. (2001). Studies of Murine Schistosomiasis Reveal Interleukin–13 Blockade As A Treatment for Established and Progressive Liver Fibrosis. Hepatology. https://doi.org/10.1053/jhep.2001.26376

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.